miR-4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway

HIROTAKA FURUKE*, HIROTAKA KONISHI*, TOMOHIRO ARITA, SATOSHI KATAOKA, JUN SHIBAMOTO, KAZUYA TAKABATAKE, WATARU TAKAKI, HIROKI SHIMIZU, YUSUKE YAMAMOTO, RYO MORIMURA, SHUHEI KOMATSU, ATSUSHI SHIOZAKI, HISASHI IKOMA and EIGO OTSUJI

Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Received February 11, 2022; Accepted April 13, 2022

DOI: 10.3892/ijmm.2022.5139

Abstract. As liver cancer (LC) is the sixth most commonly diagnosed malignancy, it is necessary to elucidate the molecular mechanisms responsible for LC progression. MicroRNAs (miRNAs/miRs) play crucial roles in tumor progression by regulating target gene expression. The present study assessed miRNA-4730 expression and function in LC. The effects of miR-4730 overexpression were examined in LC cell lines, and the target genes of miR-4730 were evaluated using microarray analysis and TargetScan data. In addition, the association between miR-4730 expression in tissue samples and the prognosis of 70 patients with LC was evaluated. miR-4730 expression was suppressed in LC tissues and cell lines. miR-4730 overexpression suppressed cell proliferation and cell cycle progression and promoted apoptosis. High mobility group A1 (HMGA1) was revealed as the direct target of miR-4730 using luciferase reporter assay, and the inhibition of downstream integrin-linked kinase (ILK) expression and Akt or glycogen synthase kinase 3β (GSK3β) phosphorylation was confirmed. The lower expression of miR-4730 in tissue samples was significantly associated with a worse recurrence-free survival of patients with LC. On the whole, miR-4730 suppressed tumor progression by directly targeting HMGA1 and inhibiting the ILK/Akt/GSK3β pathway. miR-4730 thus has potential for use as a prognostic marker and may prove to be a therapeutic target for miRNA-based therapies.

Introduction

Liver cancer (LC) is the sixth most commonly diagnosed malignancy and was the fourth leading cause of cancer-related mortality worldwide in 2018, with ~841,000 new cases and 782,000 related deaths (1). Although there have been notable developments in surgical techniques and in the peri-operative management of LC, the prognosis following curative treatments remains poor due to tumor progression and the high recurrence rate (2). The 5-year survival rate for patients with LC has been shown to be 15-38% in the USA (3-5). The risk factors for LC include hepatitis B (HBV) and hepatitis C virus (HCV) infection (6). Alcoholic cirrhosis, non-alcoholic fatty liver disease and co-infection with human immunodeficiency virus may also contribute to the occurrence of LC. Chronic hepatitis, liver fibrosis and molecular alternations in hepatocytes are promoted by these hepatic diseases, and these changes increase cell proliferation and survival, eventually leading to the development of LC (6). Moreover, the molecular changes in LC are associated with tumor malignancies. Thus, it would be beneficial to elucidate the molecular mechanisms related to the occurrence, progression and recurrence of LC in order to improve prognosis.

MicroRNAs (miRNAs/miRs) are small, endogenous, non-coding RNAs consisting of ~22 nucleotides (7). They regulate target gene expression by binding to the 3'-untranslated region (UTR) of mRNAs (7). They play crucial roles in the progression of various types of cancer, such as gastric (8), esophageal (9), colorectal (10) and pancreatic (11) cancer. A variety of miRNAs have been shown to be associated with the progression of LC by affecting oncogenesis, tumor development, cell proliferation, cell cycle regulation or apoptosis (12). As previously demonstrated, miR-657 promotes tumorigenesis by targeting transducin-like enhancer protein 1 (13) and miR-1181 promotes cell growth by regulating the expression of axis inhibition protein 1 (14). miR-4730 thus has potential for use as a prognostic marker and may prove to be a therapeutic target for miRNA-based therapies.

Key words: miR-4730, high mobility group A1, liver cancer, tumor suppression, microRNA
results of the Kaplan Meier plotter, which is a large database evaluating the association between mRNA expression and prognosis in 21 types of cancer (http://kmplot.com/), the lower expression of miR-4730 in patients with LC is associated with a poor prognosis. However, to the best of our knowledge, no studies to date have clarified the association between miR-4730 expression and the prognosis of patients with LC. Moreover, functions and target genes of miR-4730 were not identified in previous studies. The present study thus aimed to investigate the association between miR-4730 expression and the prognosis of patients with LC. In addition, the molecular functions and target genes of miR-4730 were investigated using LC cell lines.

Materials and methods

Patients and clinical samples. A total of 148 consecutive patients who underwent curative surgery for LC between 2014 and 2018 at the University Hospital, Kyoto Prefectural University of Medicine were retrospectively reviewed. Patients who had undergone surgery for recurrent lesions or with any antitumor therapies prior to surgery were excluded, and 70 patients were enrolled in total. Total RNA was extracted from the formalin-fixed paraffin-embedded (FFPE) tissue samples of these patients. Non-tumorous liver tissue was collected from the peritumoral liver tissue of the patients with LC. Tumor staging and clinicopathological factors were classified according to the 8th edition of the UICC/TNM staging system (18) and pathological features were diagnosed by pathologists. The treatment policy was selected according to the Clinical Practice Guidelines for Hepatocellular Carcinoma 2017 (19).

The present study was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent was obtained from all patients prior to surgery. The present study was reviewed and approved by the Institutional Ethics Review Board of the University Hospital, Kyoto Prefectural University of Medicine (approval no. ERB-C-1359-2).

Cells and cell culture. The following LC cell lines were used in the present study: The Li-7 cell line (RBRC-RCB1941, lot no. 356-12) was purchased from the RIKEN BioResource Center, and the HepG2 (JCRB1054, lot no. 04202017), HuH-7 (JCRB0403, lot no. 10192018), PLC/PRF/5 (JCRB0406, lot no. 12142015) cell lines were purchased from the JCRB Cell Bank. Human umbilical vein endothelial cells (HUVECs; D10011, lot no. 434Z003) were purchased from Promo cell), and the human normal esophageal squamous epithelial cell line, Het-1A (CRL-2692, lot no. 63598569), was purchased from the American Type Culture Collection (ATCC). These non-LC cell lines were used as a control. Li-7 and Het-1A cells were maintained in Roswell Park Memorial Institute medium (Nakalai Tissue), supplemented with 10% fetal bovine serum (FBS; System Biosciences). The HepG2, HuH-7, and PLC/PRF/5 cells were maintained in Dulbecco’s modified Eagle’s medium (Nakalai Tissue), supplemented with 10% fetal bovine serum (FBS; System Biosciences). HUVECs were cultured in an endothelial basal medium (EBM; Lonza Group, Ltd.) with endothelial growth supplement Single Quots (EGM-2; Lonza Group, Ltd.). All cell lines were cultured in a humidified incubator at 37°C with 5% carbon dioxide.

RNA extraction and quantification of miRNA and mRNA expression using reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from the FFPE tissue samples using an AllPrep DNA/RNA FFPE Kit (Qiagen GmbH) and from the cultured cells using a miRNeasy Mini kit (Qiagen GmbH) according to the manufacturer's protocol. The reverse transcription reaction was performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol; for 10 min at 25°C, followed by 2 h at 37°C and 5 min at 85°C. miRNA and mRNA expression levels were measured using RT-qPCR with a StepOnePlus PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), and cycle threshold (Ct) values were calculated using StepOne Software v2.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 10 min at 95°C, followed by 40 cycles for 15 sec at 95°C, for 30 sec at 55°C, and for 30 sec at 72°C. TaqMan MicroRNA Assays, hsa-miR-4730 (Assay ID: 462061_mat) and RNU6B (Assay ID: 001093) and TaqMan Gene Expression Assays, high mobility group A1 (HMGA1) (Assay ID: Hs00852949_g1) and beta-actin (Assay ID: Hs01060665_g1), were used as the primer sets (Thermo Fisher Scientific, Inc.). The results were evaluated using the 2^(-ΔΔCt) method relative to the expression level of RNU6B for miRNAs and beta-actin for mRNAs (20).

Transfection of miRNA mimic and control vector. miR-4730 mimic (Assay ID: MC21609; Thermo Fisher Scientific, Inc.) and control vector (Negative Control #1; Thermo Fisher Scientific, Inc.) were used for overexpression experiments. These were transfected into the Li-7 and HepG2 cells at a final concentration of 3 nM using a Lipofectamine 2000® reagent (Thermo Fisher Scientific, Inc.) for 24 h at 37°C according to the manufacturer's protocol. Overexpression was confirmed in total RNA extracted 48 h following transfection using RT-qPCR.

Western blot analysis. Protein samples were extracted using the Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Inc.). The protein concentration was measured using the Protein Assay Rapid kit Wako II (FUJIFILM Wako Pure Chemical Corporation) and adjusted to 20 µg per sample. Each protein sample was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene difluoride membranes (GE Healthcare; Cytiva). The membranes were blocked using Tris-buffered saline with 0.05% Tween-20 (TBST) including 5% bovine serum albumin (MilliporeSigma) for 1 h at room temperature and then incubated with the following primary antibodies at 4°C overnight. The membranes were washed with TBST to remove excess primary antibodies and incubated with anti-rabbit (#7074S) or anti-mouse (#7076S) secondary antibodies (both from Cell Signaling Technology, Inc.) at room temperature for 1 h, and proteins were detected using the ECL Plus Western Blotting Detection System (GE Healthcare; Cytiva). Densitometric analysis of the blots was performed using ImageJ software bundled with Java 1.8.0_172 (National Institutes of Health).
The monoclonal antibodies used in the present study were the following: Anti-HMGA1 (1:10,000 dilution, anti-rabbit, cat. no. ab129153) and anti-integrin-linked kinase (ILK) (1:1,000 dilution, anti-rabbit, cat. no. ab196013) (all from Abcam), anti-Akt (1:2,000 dilution, anti-mouse, cat. no. 2920S), anti-phosphorylated (p)-Akt (1:2,000 dilution, anti-rabbit, cat. no. 4060S), anti-glycogen synthase kinase 3β (GSK3β; 1:1,000 dilution, anti-rabbit, cat. no. 5676S), anti-p-GSK3β (1:1,000 dilution, anti-rabbit, cat. no. 5558S) (all from Cell Signaling Technology, Inc.), and anti-β-actin (1:20,000 dilution, anti-mouse, cat. no. A2228-200UL, MilliporeSigma) antibodies.

**Microarray analysis.** miR-4730 mimic and control vector was introduced into the Li-7 and HepG2 cells. Total RNA was extracted following 48 h of incubation at 37°C, and the purity of the RNA was evaluated using a NanoDrop ND-2000 Spectrophotometer (Thermo Fisher Scientific, Inc.). These samples were submitted to an expression array analysis (Human Clariom S Array; Thermo Fisher Scientific, Inc.). The results were arranged in order by fold change between the mimic- and control vector-transfected cells, and candidate target genes were selected using TargetScan data (http://www.targetscan.org). The probability of being a target gene was ranked by the weighted context++ score (the more negative the score, the stronger the suppression of expression).

**Cell proliferation assay.** The Li-7 and HepG2 cells were seeded at 2.0x10^4 cells/well in a 24-well plate. The number of viable cells was evaluated using a colorimetric water-soluble tetrazolium salt assay (Cell Counting Kit-8; Dojindo Laboratories, Inc.). The cell count was assessed at 0, 24, 48 and 72 h following miR-4730 mimic transfection. An absorbance value was measured at a wavelength of 450 nm using Multiskan FC (cat. no. 51119000, Thermo Fisher Scientific, Inc.) with Skanlt software 3.1.

**Cell cycle assay.** The Li-7 and HepG2 cells were seeded at 1.0x10^5 cells/well in a 6-well plate. Each proportion of the cell cycle was analyzed at 48 h following transfection with the miR-4730 mimic using flow cytometry, BD Accuri C6 (BD Biosciences). Cells were detached from the plate and collected with medium containing 1% fetal bovine serum and 0.53 mg/ml EDTA.
Table I. Association between miR-4730 expression and clinicopathological features of patients with liver cancer.

| Variables                  | No. of patients (n=70) | T/NT >0.67 (n=35) | T/NT ≤0.67 (n=35) | P-value<sup>a</sup> |
|----------------------------|------------------------|-------------------|------------------|--------------------|
| Age (years)                |                        |                   |                  | 1.000              |
| >70                        | 40                     | 20                | 20               | (57%)              |
| ≤70                        | 30                     | 15                | 15               | (43%)              |
| Sex                        |                        |                   |                  | 0.032              |
| Male                       | 50                     | 29                | 21               | (83%)              |
| Female                     | 20                     | 6                 | 14               | (17%)              |
| Viral infection            |                        |                   |                  | 0.046              |
| HBV, HCV                   | 44                     | 18                | 26               | (51%)              |
| Others                     | 26                     | 17                | 9                | (49%)              |
| AFP (ng/ml)                |                        |                   |                  | 0.780              |
| >20                        | 17                     | 8                 | 9                | (23%)              |
| ≤20                        | 53                     | 27                | 26               | (77%)              |
| IcGR15 (%)                 |                        |                   |                  | 0.065              |
| >15                        | 21                     | 7                 | 14               | (20%)              |
| ≤15                        | 49                     | 28                | 21               | (80%)              |
| Albumin (g/dl)             |                        |                   |                  | 0.006              |
| >3.5                       | 65                     | 35                | 30               | (100%)             |
| ≤3.5                       | 5                      | 0                 | 5                | (0%)               |
| Mass size (cm)             |                        |                   |                  | 0.758              |
| ≥5                         | 13                     | 7                 | 8                | (20%)              |
| <5                         | 57                     | 28                | 29               | (80%)              |
| Mass quantity              |                        |                   |                  | 0.999              |
| Multiple                   | 4                      | 2                 | 2                | (6%)               |
| Single                     | 66                     | 33                | 33               | (94%)              |
| Vascular invasion          |                        |                   |                  | 0.584              |
| Presence                   | 18                     | 10                | 8                | (29%)              |
| Absence                    | 52                     | 25                | 27               | (71%)              |
| T factor<sup>b</sup>       |                        |                   |                  | 0.614              |
| T2-3                       | 24                     | 13                | 11               | (37%)              |
| T1                         | 46                     | 22                | 24               | (63%)              |
| Histopathological type     |                        |                   |                  | 0.606              |
| Well differentiated        | 22                     | 10                | 12               | (29%)              |
| Other                      | 48                     | 25                | 23               | (71%)              |
| Liver fibrosis             |                        |                   |                  | 0.780              |
| F1-4                       | 53                     | 26                | 27               | (74%)              |
| F0                         | 17                     | 9                 | 8                | (26%)              |
| Recurrence                 |                        |                   |                  | 0.084              |
| Presence                   | 27                     | 10                | 17               | (29%)              |
| Absence                    | 43                     | 25                | 18               | (71%)              |

Values in bold font indicate statistically significant differences (P<0.05).<sup>a</sup>P-values were calculated using the chi-squared test.<sup>b</sup>The T factor was according to the 8th edition of the UICC/TNM staging system (18). NT, non-tumor tissue; T, tumor tissue; HBV, hepatitis type B virus; HCV, hepatitis type C virus; AFP, alpha-fetoprotein; IcGR, indocyanine green retention.

by trypsin-EDTA, treated with 200 µl 0.2% Triton X-100, and stained with 500 µl PI/RNase staining buffer (Becton, Dickinson and Company) for 15 min at room temperature. In total, 10,000 cells were measured in each sample.

Cell apoptosis assay. The Li-7 and HepG2 cells were seeded at 8.0x10³ cells/well in a 6-well plate. Apoptotic rates were evaluated at 48 h following transfection with miR-4730 mimic using an Annexin V-FITC kit (Beckman Coulter,
Inc.). The proportion of early and late apoptotic cells was measured using flow cytometry with BD Accuri C6. In total, 10,000 cells were measured in each sample.

### Table II. Univariate and multivariate analyses for recurrence-free survival.

| Variables                  | No. of patients (n=70) | Univariate | Multivariate |
|----------------------------|------------------------|------------|--------------|
|                            |                        | RFS (%)    | P-value<sup>a</sup> | HR  | 95% CI | P-value<sup>b</sup> |
| Age (years)                |                        |            | 0.257        |     |        |                |
| >70                        | 40                     | 54.5       |              |     |        |                |
| ≤70                        | 30                     | 29.4       |              |     |        |                |
| Sex                        |                        |            | 0.601        |     |        |                |
| Male                       | 50                     | 36.1       |              |     |        |                |
| Female                     | 20                     | 63.5       |              |     |        |                |
| Virus                      |                        |            | 0.501        |     |        |                |
| HBV, HCV                   | 44                     | 47.0       |              |     |        |                |
| Other                      | 26                     | 39.8       |              |     |        |                |
| AFP (ng/ml)                |                        |            | 0.908        |     |        |                |
| >20                        | 17                     | 42.1       |              |     |        |                |
| ≤20                        | 53                     | 44.5       |              |     |        |                |
| IcGR15 (%)                 |                        |            | 0.080        |     |        |                |
| >15                        | 21                     | 22.8       |              |     |        |                |
| ≤15                        | 49                     | 49.9       |              |     |        |                |
| Albumin (g/dl)             |                        |            | 0.258        |     |        |                |
| >3.5                       | 65                     | 44.6       |              |     |        |                |
| ≤3.5                       | 5                      | 40.0       |              |     |        |                |
| Mass size (cm)             |                        |            | 0.034        | 1.37| 0.70-2.47| 0.331         |
| >5                         | 13                     | 0          |              |     |        |                |
| ≤5                         | 57                     | 50.8       |              |     |        |                |
| Mass quantity              |                        |            | 0.047        | 1.88| 0.56-4.68| 0.267         |
| Multiple                   | 4                      | 0          |              |     |        |                |
| Single                     | 66                     | 48.3       |              |     |        |                |
| Vascular invasion          |                        |            | 0.852        |     |        |                |
| Presence                   | 18                     | 34.5       |              |     |        |                |
| Absence                    | 52                     | 46.8       |              |     |        |                |
| T factor<sup>c</sup>       |                        |            | 0.125        |     |        |                |
| T2-3                       | 24                     | 22.1       |              |     |        |                |
| T1                         | 46                     | 54.7       |              |     |        |                |
| Histopathological type     |                        |            | 0.713        |     |        |                |
| Well-differentiated        | 22                     | 45.1       |              |     |        |                |
| Other                      | 48                     | 43.7       |              |     |        |                |
| Liver fibrosis             |                        |            | 0.110        |     |        |                |
| F1-4                       | 53                     | 37.5       |              |     |        |                |
| F0                         | 17                     | 76.9       |              |     |        |                |
| miR-4730                   |                        |            | 0.007        | 1.98| 1.22-3.22| 0.005         |
| T/NT ≤0.67                 | 35                     | 27.2       |              |     |        |                |
| T/NT >0.67                 | 35                     | 57.8       |              |     |        |                |

Values in bold font indicate statistically significant differences (P<0.05). *P-values were calculated was calculated using the log-rank test; †P-values were calculated using the Cox hazard model; §Determined according to the 8th edition of the UICC/TNM staging system (18). RFS, recurrence-free survival; HR, hazard ratio; 95% CI, 95% confidence interval; HBV, hepatitis type B virus; HCV, hepatitis type C virus; AFP, alpha-fetoprotein; IcGR, indocyanine green retention; NT, non-tumor tissue; T, tumor tissue.

Luciferase reporter assay. Wild-type (WT) or mutant-type (MT) 3′-UTR sequences of the HMGA1 were inserted into the pmirGLO vectors (Promega Corporation), prior to the
FURUKE et al: miR-4730 SUPPRESSES LC

Luciferase assays. Cells were seeded at 1.0x10⁴ cells/well in a 96-well black plate (Thermo Fisher Scientific, Inc.). After 24 h of culture, 100 ng of the WT or MT vector and 3 nM of miR-4730 mimic were transfected into the cultured cells using the Lipofectamine 2000® reagent (Thermo Fisher Scientific, Inc.). The cells were incubated for 48 h at 37˚C before the measurements. This assay was performed using the dual Luciferase Reporter Assay kit (Promega Corporation) in accordance with the manufacturer’s protocol. Luminous absorbance was measured using the GloMax® Discover Microplate Reader (Promega Corporation). The luciferase activity of Renilla was used as the control reporter for normalization.

Statistical analysis. The Kaplan-Meier method was used to analyze recurrence-free survival (RFS) and overall survival (OS), and the differences were evaluated using the log rank test. Prognosis was examined using univariate and multivariate analysis with the cox hazard proportional model. The hazard ratio and 95% confidence interval were calculated using JMP 10 software (SAS Institute, Inc.). The Wilcoxon t-test was used.
to evaluate the differences among the paired non-parametric variables, the Mann-Whitney U-test among unpaired non-parametric variables, and the unpaired t-test among unpaired parametric variables. Correlation analysis was performed using Spearman's rank correlation coefficient. The Chi-squared test was used for categorical variables. Statistical tests used in the present study were two-sided, and a P-value <0.05 was considered to indicate a statistically significant difference. Data were presented in the figures as the mean ± standard deviation (SD). All statistical analyses were performed using JMP 10 software (SAS Institute, Inc.).

Results

miR-4730 expression in tissue samples and its association with clinical features of patients with LC. miR-4730 expression in the FFPE tissue samples (n=70) was significantly higher in the non-tumorous tissue than in the tumor tissue (P=0.006, Fig. 1A). As shown in Fig. 1B, RFS following surgery was associated with miR-4730 expression. Patients were divided into the high and low groups according to the median value of miR-4730 expression in the tumor divided by that in the non-tumorous tissue (T/NT). The cut-off value was determined as 0.67. RFS was significantly worse in the low expression group (P=0.007). However, there was no difference in OS between these two groups (P=0.786, Fig. S1).

The association between miR-4730 expression and the clinicopathological features of patents with LC is presented in Table I. Viral infection (HBV or HCV), the serum albumin level and sex were associated with miR-4730 expression in the tumor tissue (P=0.046, P=0.006 and P=0.032, respectively). Furthermore, miR-4730 expression tended to be associated with indocyanine green retention (P=0.065) and the recurrence rate (P=0.084), although this was not significant. Survival analysis in the univariate analysis revealed that a mass size >5 cm (P=0.034), multiple tumors (P=0.047) and a lower expression of miR-4730 in the tumor tissue (P=0.007) were significantly associated with a poor RFS rate (Table II). Moreover, in the multivariate analysis, only miR-4730 expression was an independent prognostic factor (hazard ratio, 1.98; 95% confidence interval, 1.22-3.22, P=0.005).

Functions of miR-4730 in LC cell lines. miR-4730 expression in LC cell lines was significantly lower than that in non-LC cell lines (P=0.003, Fig. 1C). The Li-7 and HepG2 cell lines were selected for further examination. miR-4730 expression in both cell lines was sufficiently elevated following transfection with miR-4730 mimic (Fig. 2A). The proliferative ability of

---

Figure 3. Examination of direct target genes of miR-4730. (A) Results of microarray analysis of the candidate target genes of miR-4730 were arranged in order of the fold change of mock and mimic transfection. The candidate gene, HMGA1, is marked in the plot. (B) HMGA1 expression was analyzed using reverse transcription-quantitative PCR and western blot analysis following the overexpression of miR-4730. HMGA1 expression was significantly decreased. (C) Results of the luciferase reporter assay demonstrated that the overexpression of miR-4730 decreased luciferase activity following transfection with the WT vector of HMGA1. The WT or MT sequence of HMGA1 is shown on the right panel. Experiments were performed in triplicate and results are shown as the mean ± SD. An unpaired t-test was used to analyze the data ("P<0.05 and "; P<0.01, vs. mock group or MT). HMGA1, high mobility group A1; WT, wild-type; MT, mutant-type.
miR‑4730 SUPPRESSES LC

FURUKE et al.

The proportion of cells in the G0/G1 phase was significantly increased following transfection with miR‑4730 mimic (Fig. 2c). In the apoptosis assay, the number of early apoptotic cells was also significantly increased following transfection with miR‑4730 mimic (Fig. 2d).

Search for the candidate target gene of miR‑4730. Changes in gene expression following miR‑4730 overexpression were examined using microarray analysis, and HMGA1, which was ranked higher in both Li‑7 and HepG2 cell lines (Fig. 3A), was selected as a candidate target gene of miR‑4730 (the weighted context++ score of miR‑4730 and HMGA1 was -0.39 according to the TargetScan database).

Association between miR‑4730 and HMGA1 expression. The association between miR‑4730 and HMGA1 expression was analyzed using RT‑qPCR and western blot analysis (Fig. 3B). The mRNA and protein expression levels of HMGA1 were significantly decreased following miR‑4730 overexpression. Moreover, miR‑4730 overexpression decreased the luciferase activity of the vector containing the target sequence of HMGA1 (WT vector), but not that of the vector containing the mutant sequence (MT vector) (Fig. 3C). Thus, HMGA1 was a direct target gene of miR‑4730.

HMGA1 expression and downstream signaling pathway. The expression of HMGA1 in tumor tissue was found to negatively correlate with the expression of miR‑4730 (P=0.049, Spearman's rank correlation coefficient=-0.268, Fig. 4A). Such
a correlation could not be confirmed in the non-tumorous tissue (Fig. S2). As a previous study found that HMGA1 regulated the ILK/Akt/GSK3β signaling pathway and promoted the proliferation of LC (21), the present study examined the alterations in protein expression in this downstream pathway using western blot analysis. The protein expression levels of HMGA1, ILK, p-Akt and p-GSK3β were downregulated in both the Li-7 and HepG2 cell lines following miR-4730 overexpression (Fig. 4B). As shown in Fig. 4C, miR-4730 overexpression inhibited HMGA1 and the ILK/Akt/GSK3β downstream signaling pathway.

**Discussion**

Gene regulation is one of the main factors responsible for the progression of LC (6). miRNAs regulate levels of gene expression by binding to the 3'-UTR of their target mRNAs and subsequently inducing their cleavage or translational repression (7). miRNAs can function as promoters and suppressors of LC by inhibiting their target genes (12); however, the functions and target genes of various miRNAs remain unknown. It is thus of utmost interest to reveal the characteristics of miRNAs in the regulation of LC progression in order to improve the therapeutic effects or prognosis. The present study revealed that miR-4730 suppressed the progression of LC by targeting HMGA1 and inhibiting the downstream ILK/Akt/GSK3β signaling pathway. The association between HMGA1 and its downstream pathway was revealed in a previous study (21). However, to the best of our knowledge, the present study is the first to clarify the molecular functions of miR-4730 and its association with HMGA1 in LC. Furthermore, the lower expression of miR-4730 in tumor tissue was related to a poor RFS of patients with LC. Thus, miR-4730 is a novel prognostic marker for patients with LC.

HMGA1 is a non-histone chromatin protein and regulates the transcription of several genes by either enhancing or suppressing transcription factors (22). It directly binds to DNA using basic AT-hook domains and modifies their conformation, which consequently facilitates the binding of transcriptional factors. By generating the multiprotein stereospecific complex bound to DNA, HMGA1 regulates expression of various genes. It has previously been reported that the expression of HMGA1 in adult tissue is typically lower (23); however, in various malignant cells the overexpression of HMGA1 has been observed (24). This overexpression of HMGA1 activates tumor proliferation, anti-apoptotic mechanisms, metastasis, angiogenesis, immune evasion, chromosomal instability and epithelial mesenchymal transition (25). In the present study, miR-4730 directly targeted HMGA1 in LC cell lines, and a negative correlation was observed between the expression of miR-4730 and HMGA1 in clinical LC samples. Thus, the overexpression of HMGA1 due to the suppression of mi-4730 expression contributes to LC progression.

Shi *et al* (26) also reported that HMGA1 was highly expressed in LC tissue and miR-195-5p directly suppressed HMGA1 expression. The base sequence of miR-4730 and miR-195-5p differ from each other, and these miRNAs inhibit different regions of HMGA1. Considering the mechanism of miRNA that affects the expression of a number of different target genes (7), there are less functional associations between miR-195-5p and miR-4730 in LC. miR-195-5p has been reported to regulate a variety of genes other than HMGA1 in LC, such as for example metastasis-associated in colon cancer-1 (27), centrosomal protein 55 (28) and programmed cell death 4 (29). Therefore, there is no doubt that miR-195-5p also suppresses the progression of LC; however, it appears that there is no association between the functions of miR-4730 and miR-195-5p in inhibiting HMGA1 expression.

The ILK/Akt/GSK3β signaling pathway is one of the downstream pathways of HMGA1 (30). Liu *et al* (21) reported that HMGA1 participated in LC progression through the ILK/Akt/GSK3β signaling pathway. The knockdown of HMGA1 has been shown to decrease the expression of ILK, and ILK downregulation suppresses the phosphorylation of Akt and GSK3β (31). Akt is known as a critical mediator of growth factor-induced cell proliferation by activating mammalian target of rapamycin (32). The activation of Akt suppresses apoptosis by phosphorylating certain substrates, such as pro-apoptotic Bad, caspase-9 and Forkhead transcription factor FoxO3a (33), and also upregulates cell cycle-promoting genes, such as cyclin-dependent kinase 1, proliferating cell nuclear antigen and telomerase reverse transcriptase (34). In the present study, miR-4730 overexpression markedly inhibited the ILK/Akt/GSK3β pathway, and the functions of LC cells were suppressed. These results suggest that miR-4730 has potent tumor-suppressive abilities in LC and may be used for miRNA-based therapy by directly suppressing the function of HMGA1.

In the present study, miR-4730 expression was found to be significantly lower in tumor tissue than in non-tumorous tissue. It was also found that HBV or HCV infection was associated with a lower expression of miR-4730 in tumor tissue. A previous study reported that HMGA1 expression in LC cell lines expressing the full-length HBV genome was upregulated (35). HBV is a circular and double-stranded DNA virus that invades hepatocytes and encodes viral proteins (35). Thus, HBV infection can affect gene expression in hepatocytes and may upregulate HMGA1 expression following the suppression of miR-4730 expression.

The present study revealed that the lower expression of miR-4730 in tumor tissue was associated with a poor RFS. The recurrence of LC is considered to be the onset of new LC rather than the recurrence of the initial lesion. Liver tumor tissue with a lower miR-4730 expression may have a higher malignant ability or carcinogenicity; however, further investigations is required to clarify the mechanisms responsible for the decrease in miR-4730 expression. In the present study, a lower miR-4730 expression was associated with HBV or HCV infection and a decrease in liver function. Therefore, chronic inflammation of the liver tissue may affect miR-4730 expression. On the other hand, non-surgical treatments are often selected for the recurrence of LC. Even if surgical treatments are selected, partial resections are mostly performed. In these cases, peritumoral liver tissue cannot be sufficiently collected and it is difficult to fully analyze miR-4730 expression in non-tumorous liver tissue.

There are some limitations to the present study which should be mentioned. It was difficult to reach more general conclusions due to the small patient population and limited
sample holding status. In the present study, the effects of the knockdown of miR-4730 expression were not examined due to the lower expression of miR-4730 in the majority of LC cell lines than in non-LC cell lines. The opposite effect using an inhibitor of miR-4730 may need to be examined in other cell lines. Moreover, the effects of HMGA1 overexpression on proliferation or apoptosis were not examined. Although the present study focused on miR-4730, there might be other candidate miRNAs which influence the expression of HMGA1. Thus, further studies are warranted.

In conclusion, the present study demonstrated that miR-4730 expression in LC suppressed tumor progression by directly targeting HMGA1 and inhibiting the downstream pathway. miR-4730 is a novel prognostic marker for patients with LC and may become a therapeutic target through the HMGA1 pathway.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available in the Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196261).

Authors’ contributions
HF and HK conceived the study design, performed the experiments, and wrote the initial manuscript drafts. HK, TA, SKa, JS, KT, WT and EO discussed the progress and analyzed the results of this research and performed critical editing of the manuscript. HS, SKo, AS, YY, RM and HI collected the clinical samples and carefully considered the research plans and contents. HF and HK confirm the authenticity of all the raw data. All authors have read and agreed to the published version of the manuscript.

Ethics approval and consent to participate
The present study was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent was obtained from all patients prior to surgery. This study was reviewed and approved by the Institutional Ethics Review Board of the University Hospital, Kyoto Prefectural University of Medicine (approval no. ERB-c-1359-2).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Fornet A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
3. Altokruse SF, Henley SJ, Cucinelli JE and McGlynn KA: Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 109: 542-553, 2014.
4. Zhang G, Li R, Deng Y and Zhao L: Conditional survival of patients with hepatocellular carcinoma: Results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol 12: 515-523, 2018.
5. Xu L, Kim Y, Soloverato G, Gani F and Pawlik TM: Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr 5: 43-52, 2016.
6. Villanueva A: Hepatocellular Carcinoma. N Engl J Med 380: 1450-1462, 2019.
7. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Link A and Kupcinskas J: MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J Gastroenterol 24: 3313-3329, 2018.
9. Hamada K, Baba Y, Ishimoto T, Shigaki H, Kosumi K, Yoshiida N, Watanabe M and Baba H: The role of microRNA in hepatocellular-squamous cell carcinoma. J Gastroenterol 51: 520-530, 2016.
10. Chen B, Xia Z, Deng YN, Yang Y, Zhang P, Zhu H, Xu N and Liang S: Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol 9: 180212, 2019.
11. Rawat M, Kadian K, Gupta Y, Kumar A, Chain PSG, Kovbasnjuk O, Kumar S and Parasher G: MicroRNA in pancreatic cancer: From biology to therapeutic potential. Genes (Basel) 10: 752, 2019.
12. Oura K, Morishita A and Masaki T: Molecular and functional roles of MicroRNAs in the progression of hepatocellular carcinoma-A review. Int J Mol Sci 21: 8362, 2020.
13. Zhang L, Yang L, Liu X, Chen W, Chang L, Chen L, Loera S, Chu P, Huang WC, Liu YR and Yen Y: MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology 57: 1919-1930, 2013.
14. Song Z, Yu Z, Chen L, Zhou Z, Zou Q and Liu Y: MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomed Pharmacother 119: 109397, 2019.
15. Wong QW, Lung KW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257-269, 2008.
16. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology 58: 642-653, 2013.
17. Yang W, Ju HY and Tian XF: Hsa-miR-4730 as a new and potential diagnostic and prognostic indicators for pancreatic cancer. Eur Rev Med Pharmacol Sci 24: 8801-8811, 2020.
18. Union for International Cancer Control: TNM Classification of Malignant Tumours. Brierley JD, Gospodarowicz MK and Wittekind C (eds). 8th edition. John Wiley & Sons, Inc., Hoboken, NJ, 2017.
19. The Japan Society of Hepatology: Clinical Practice Guidelines for Hepatocellular Carcinoma 2017. Kanehara & co Ltd., Tokyo, 2017.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
21. Liu L, Zhang S, Hu L, Liu L, Guo W and Zhang J: HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3β signaling pathway. Mol Med Rep 16: 9287-9294, 2017.
22. Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910, 2007.
23. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trappasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, et al: High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13: 2439-2446, 1996.
24. Wang Y, Hu L, Zheng Y and Guo L: HMGA1 in cancer: Cancer classification by location. J Cell Mol Med 23: 2293-2302, 2019.
25. Sumter TF, Xian L, Huso T, Koo M, Chang YT, Almasri TN, Chua L, Inglis C, Reid D and Resar LM: The high mobility group A1 (HMGA1) transcriptome in cancer and development. Curr Mol Med 16: 353-393, 2016.
26. Shi M, Lv X, Zhu M, Dong Y, Hu L, Qian Y, Fan C and Tian N: HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p. Anticancer Drugs 33: e273-e285, 2022.
27. Wan T, Zheng J, Yao R, Yang S, Zheng W and Zhou P: LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACCI pathway. Ann Hepatol 20: 100258, 2021.
28. Liu LX, Liu B, Yu J, Zhang DY, Shi JH and Liang P: SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates the hepatocellular carcinoma tumorigenesis through targeting CEP55 via sponging miR-195-5p. Biochem Biophys Res Commun 533: 779-785, 2020.
29. Huang D, Wei Y, Zhu J and Wang F: Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene 714: 143994, 2019.
30. Reeves R: Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 277: 63-81, 2001.
31. Chan J, Ko FC, Yeung YS, Ng IO and Yam JW: Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One 6: e16984, 2011.
32. Revathidevi S and Munirajan AK: Akt in cancer: Mediator and more. Semin Cancer Biol 59: 80-91, 2019.
33. Spokoini R, Kfir-Erenfeld S, Yefenof E and Sionov RV: Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol 24: 1136-1150, 2010.
34. Koundourou N and Poulogiannis F: Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. Front Oncol 8: 160, 2018.
35. Nakanishi F, Ohkawa K, Ishida H, Hosui A, Sato A, Hiramatsu N, Ueda K, Takehara T, Kasahara A, Sasaki Y, et al: Alteration in gene expression profile by full-length hepatitis B virus genome. Intervirology 48: 77-83, 2005.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.